Rethinking brain health
We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative conditions.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative conditions.
This gives us the potential to revolutionise how people think about brain health.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Our products
Pharma/Biotech
- Measures you can trust
- Get more from your MRI
- Run targeted, more efficient clinical trials
- Efficient use of technology across multiple conditions
Clinical
- Supporting patient care
- Helping clinicians in their diagnosis
- Differential patterns of brain changes
- Accurately tracking changes
- Proactive brain health
Latest news
Oxford Brain Diagnostics Joins International Consortium in $650K Fox Foundation Grant
Oxford Brain Diagnostics is collaborating with top North American institutions on a 24-month project to detect early-stage Parkinson’s using advanced MRI and their FDA cleared technology - Cortical Disarray Measurement. Funded by The Michael J. Fox Foundation, the initiative aims to develop objective biomarkers to improve diagnosis, treatment, and clinical trials in PD.
BGF backed Oxford Brain Diagnostics to roll out technology for early diagnosis of dementia
CDM Insights, powered by Cortical Disarray Measurement, is now FDA 510(k) cleared and UKCA approved. Backed by BGF and active in clinical trials, OBD is expanding in the US and UK to combat diseases like Alzheimer’s, Parkinson’s, and Multiple Sclerosis.
Gail Marcus joins OBD Board as Chair Person
We are pleased to welcome Gail Marcus as the new Chair of our Board. Gail brings extensive experience in healthcare, biotech, and diagnostics, with leadership roles at Fortune 100 companies like CIGNA and United Healthcare, as well as early-stage ventures. Her expertise in governance, finance, and risk management will be instrumental in advancing our mission to transform brain health. We also extend our heartfelt thanks to Andrew Barker for his six years of dedicated leadership as Chair.
Oxford Brain Diagnostics has been granted FDA Clearance for its novel MRI Software – CDM Insights
CDM Insights, powered by Cortical Disarray Measurement, is now FDA 510(k) cleared. This non-invasive tool analyzes standard MRI scans to detect brain microstructure changes, supporting early diagnosis of conditions like Alzheimer’s.
